Y-mAbs Therapeutics Inc. (Y-mAbs) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer based on a range of technologies licensed from Memorial Sloan Kettering Cancer Center. Its mission is to become the world leader in developing better and safer antibody-based pediatric oncology products addressing clear unmet medical needs. Y-mAbs also seeks to advance and expand its product pipeline into certain adult cancer indications and to leverage its extensive drug development capabilities and platform technology towards the creation of new types of bispecific antibodies.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Granted Rare Pediatric Disease Designation by FDA
Y-mAbs Announces Data to be Presented at SIOP 2021
Y-mAbs Announces Priority Review of BLA for DANYELZA® (naxitamab-gqgk) in China